Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05081700 · ClinicalTrials.gov registry record
A Systems Approach to Understanding Disease Processes in Multiple Sclerosis
A clinical trial, sponsored by Providence Health & Services.
- Completed
- Registry status
- 14
- Enrollment target
NCT05081700: Completed study, sponsored by Providence Health & Services.
NCT05081700 is a clinical trial that has completed, run by Providence Health & Services. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05081700 has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This pilot study will establish a proof of concept for using a systems biology approach to characterize the dynamics of MS disease processes. The primary objective of the study is to identify multi-omic (genetic, proteomic, biochemical and/or microbial) factors that correlate with clinical and subclinical MS disease activity. Identification of such biomarkers could have an immediate clinical utility in identification of MS patients prone to more aggressive disease earlier in their disease course, thus affording the opportunity to better individualize therapy. In addition, insights from better understanding of the complex interplay of various systems biology factors should improve our understanding of MS in general. The study will recruit 14 patients with relapsing MS who are initiating treatment with ocrelizumab, and follow them for 30 months.
Primary Outcome
Number of participants free of MS relapse at 6, 12, and 30 months divided by total number of participants.
Interventions
- DRUG All patients in the study will be treated with ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2023-11-03 |
What the finished NCT05081700 record still lists
NCT05081700 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which All patients in the study will be treated with ocrelizumab is the first listed.
NCT05081700 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05081700 about?
NCT05081700 is a clinical study titled "A Systems Approach to Understanding Disease Processes in Multiple Sclerosis". This pilot study will establish a proof of concept for using a systems biology approach to characterize the dynamics of MS disease processes. The primary objective of the study is to identify multi-omic (genetic, proteomic, biochemical and/or microbial) factors that correlate with clinical and subcl...
What is the current status of trial NCT05081700?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2020-05-11. Estimated completion is 2023-11-03.
What interventions are being tested in trial NCT05081700?
The interventions under investigation include: All patients in the study will be treated with ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT05081700?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy